An integrative approach to linking genes, brain, and behavior in 22q11.2 CNV's
连接 22q11.2 CNV 中的基因、大脑和行为的综合方法
基本信息
- 批准号:9759710
- 负责人:
- 金额:$ 3.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-01 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:22q22q11.2AffectAreaBehaviorBehavioralBiologicalBiological MarkersBrainClinicalCognitionCognitiveComorbidityComplexCopy Number PolymorphismDNADevelopmentDevelopmental ProcessDiGeorge SyndromeDiseaseEvolutionExhibitsFunctional disorderGene DosageGene ExpressionGeneral PopulationGenesGeneticGenetic RiskGlutamatesGoalsHeterogeneityImmuneIndividualIntellectual functioning disabilityInterventionLinkLive BirthMeasuresMedicalMental disordersModelingMutationNeuronal DifferentiationOnline Mendelian Inheritance In ManPathogenesisPathway interactionsPatternPhenotypePopulation StudyPrevalencePsychotic DisordersRecurrenceRiskRisk FactorsSchizophreniaShprintzen syndromeSpecificityStructureSurfaceSymptomsThickVariantYouthautism spectrum disorderbasebehavior measurementbrain behaviorbrain dysfunctioncognitive abilitycognitive developmentcohortconotruncal anomaly face syndromedevelopmental diseasedifferential expressiondisorder riskgenetic variantgenomic variationhigh riskimmune functioninsightmigrationmultimodalityneuron developmentneuropsychiatric disorderneuropsychiatryneurotransmissionnovelpreservationprospectiveprotective factorspsychotic symptomssocial cognitionspecific language impairmentsymptomatologytranscriptome
项目摘要
PROJECT SUMMARY / ABSTRACT
A primary challenge in uncovering biological mechanisms of developmental neuropsychiatric illnesses like
schizophrenia (SCZ) and autism spectrum disorders (ASD) is grappling with their remarkable genetic and
phenotypic heterogeneity. As such, taking a `genetics first' approach—i.e., ascertainment and comprehensive
phenotyping of individuals with specific, known genetic variants—offers an alternative, biologically-tractable
framework to dissecting genetic mechanisms underlying intermediate phenotypes of brain development,
cognition, and behavior. Copy number variants (deleted or duplicated DNA segments ≥ 50 basepairs; CNVs) at
the 22q11.2 locus are especially compelling models because they confer some of the largest known genetic
risk for psychiatric disorders and include highly conserved genes critical for brain and cognitive development.
The 22q11.2 deletion results from a 1.5–3 Mb hemizygous deletion on the long arm of chromosome 22 and
has an estimated prevalence of 1 in 3,000–4,000 live births. In addition to medical comorbidities, the deletion is
one of the greatest known genetic risks for SCZ, with a 25-fold risk increase compared to the general
population. It is also associated with greater risk for other developmental neuropsychiatric disorders such as
ASD. Yet, very little is known about the reciprocal 22q11.2 duplication phenotype, in part due to its more recent
discovery as a recurrent CNV. While the phenotype is highly variable, it appears to confer high risk for ASD
and specific language impairment. Intriguingly, multiple population-based studies have now shown the
duplication to be significantly less common in SCZ cases than in the general population, suggesting the first
putative protective mutation for SCZ. This notable distinction between risk and protective factors for SCZ
suggests that gene-dosage specificity may underlie disease evolution. This project will leverage a large cohort
of extensively phenotyped individuals with 22q11.2 deletions (n=91) or duplications (n=34), as well as
demographically comparable controls (n=82). This will be the first study to investigate reciprocal effects of
22q11.2 CNVs on gene expression, brain, and behavior. Specifically, our aims are to: (i) establish the effect of
22q11.2 CNVs on multiple cognitive and behavioral measures relevant to SCZ and/or ASD (Aim 1), (ii)
investigate transcriptome-wide dysregulation of gene expression by identifying networks of co-expressed
genes resulting from a 22q11.2 deletion versus duplication and use enrichment analysis to infer dysregulated
biological pathways (Aim 2), and (iii) probe biological pathways predictive of brain and behavioral phenotypes
in these reciprocal CNVs (Aim 3). This integrative, multimodal approach aims to elucidate biological pathways
and brain biomarkers which may differentiate risk versus protective factors for psychosis or converging factors
for ASD risk, in the context of this highly-penetrant CNV, with the primary goal of providing novel insights into
how these CNVs disrupt the brain and contribute to disease pathogenesis.
项目摘要/摘要
在揭示发育性神经精神疾病的生物学机制方面的主要挑战
精神分裂症(SCZ)和自闭症谱系障碍(ASD)正在努力解决它们显著的遗传和
表型异质性。因此,采取“遗传学优先”的方法--即,查明和全面
对具有特定已知基因变异的个体进行表型分型--提供了一种生物学上易于处理的替代方案
剖析大脑发育中间表型潜在遗传机制的框架,
认知和行为。拷贝数变异(删除或复制的DNA片段≥50碱基;CNV)在
22q11.2基因座是特别引人注目的模型,因为它们赋予了一些已知的最大的遗传
精神障碍的风险,包括对大脑和认知发育至关重要的高度保守的基因。
22q11.2的缺失是由于22号染色体长臂上1.5-3Mb的半合子缺失所致
据估计,每3,000-4,000名活产儿中就有1名。除了医学上的合并症,删除的是
已知的SCZ最大的遗传风险之一,与一般情况下相比,风险增加了25倍
人口。它还与其他发育性神经精神障碍的风险更大有关,如
ASD.然而,人们对相互作用的22q11.2重复表型知之甚少,部分原因是它最近
发现为复发性CNV。虽然表型有很高的变异性,但它似乎具有患ASD的高风险。
和特定的语言障碍。有趣的是,多项基于人群的研究现在表明
与普通人群相比,SCZ患者中的复制现象明显较少,这表明第一
推测为SCZ的保护性突变。SCZ的危险因素和保护因素之间的显著区别
提示基因剂量特异性可能是疾病进化的基础。这个项目将利用一个大的队列
具有22q11.2缺失(n=91)或重复(n=34)的广泛表型个体,以及
人口学上可比的对照(n=82)。这将是第一个研究相互影响的研究。
22q11.2 CNV对基因表达、脑和行为的影响。具体来说,我们的目标是:(I)确立
22q11.2与SCZ和/或ASD相关的多种认知和行为测量的CNV(目标1),(2)
通过鉴定共表达的网络来研究转录组范围的基因表达失调
由22q11.2缺失和复制产生的基因,并使用富集化分析来推断失调
生物学途径(目标2),和(Iii)探索预测大脑和行为表型的生物学途径
在这些相互的CNV中(目标3)。这种综合的、多模式的方法旨在阐明生物途径
和脑生物标记物,可以区分精神病的危险因素和保护因素或趋同因素
对于ASD风险,在这种高度渗透的CNV的背景下,主要目标是提供对
这些CNV是如何扰乱大脑并促进疾病发病机制的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Amy Lin其他文献
Amy Lin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Amy Lin', 18)}}的其他基金
An integrative approach to linking genes, brain, and behavior in 22q11.2 CNV's
连接 22q11.2 CNV 中的基因、大脑和行为的综合方法
- 批准号:
9920597 - 财政年份:2019
- 资助金额:
$ 3.68万 - 项目类别:
相似国自然基金
22q11.2染色体微重复影响TOP3B表达并导致腭裂发生的机制研究
- 批准号:82370906
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
22q11.2微缺失综合症中T盒转录因子Tbx1与信号接头蛋白Crkl遗传相互作用致肺动脉发育不良缺陷的机制研究
- 批准号:81170153
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
基于染色体22q11.2候选基因与腭心面综合征表型的分子诊断研究
- 批准号:81070813
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
无22q11.2区基因微缺失的心脏圆锥动脉干畸形患者中新TBX1突变体蛋白的功能研究
- 批准号:81070135
- 批准年份:2010
- 资助金额:32.0 万元
- 项目类别:面上项目
染色体22q11.2区域泌尿系统畸形关键致病基因的克隆与鉴定
- 批准号:30571867
- 批准年份:2005
- 资助金额:25.0 万元
- 项目类别:面上项目
相似海外基金
成人期へtransitionする22q11.2欠失症候群患者の移行支援プログラムの構築
为 22q11.2 缺失综合征患者过渡到成年期建立过渡支持计划
- 批准号:
24K13915 - 财政年份:2024
- 资助金额:
$ 3.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Engineered Hydrogel Platform to Improve Neural Organoid Reproducibility for a Multi-Organoid Disease Model of 22q11.2 Deletion Syndrome
一种工程水凝胶平台,可提高 22q11.2 缺失综合征多器官疾病模型的神经类器官再现性
- 批准号:
10679749 - 财政年份:2023
- 资助金额:
$ 3.68万 - 项目类别:
Outcomes and disease burden in a model of young adult multimorbidity
年轻成人多重病模型的结果和疾病负担
- 批准号:
479042 - 财政年份:2023
- 资助金额:
$ 3.68万 - 项目类别:
Operating Grants
重複障害を呈する医療的ケア児と家族の移行期における意思決定支援のPPI型研究
多重残疾儿童及其家庭过渡期决策支持的PPI型研究
- 批准号:
23H02834 - 财政年份:2023
- 资助金额:
$ 3.68万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
22q11.2欠失症候群との網羅的な比較検討によるファロー四徴症での遺伝子異常の解明
与22q11.2缺失综合征综合比较阐明法洛四联症遗传异常
- 批准号:
23K08237 - 财政年份:2023
- 资助金额:
$ 3.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating abnormalities in top-down cortical processing and behavior in a model of the 22q11.2 deletion
研究 22q11.2 缺失模型中自上而下的皮质处理和行为的异常
- 批准号:
10649058 - 财政年份:2023
- 资助金额:
$ 3.68万 - 项目类别:
Phenotypic convergence at mitochondria in copy number variant disorders
拷贝数变异性疾病中线粒体的表型趋同
- 批准号:
10723885 - 财政年份:2023
- 资助金额:
$ 3.68万 - 项目类别:
Neurodevelopmental defects of the thalamocortical pathway as a convergent feature of psychiatric disorders
丘脑皮质通路的神经发育缺陷是精神疾病的共同特征
- 批准号:
10655225 - 财政年份:2023
- 资助金额:
$ 3.68万 - 项目类别:
Improving Genetic Diagnosis for African Ancestry Populations
改善非洲血统人群的基因诊断
- 批准号:
10736833 - 财政年份:2023
- 资助金额:
$ 3.68万 - 项目类别:
The schizophrenia-associated 3q29 deletion: genetic architecture of behavioral phenotypes
精神分裂症相关的 3q29 缺失:行为表型的遗传结构
- 批准号:
10579244 - 财政年份:2023
- 资助金额:
$ 3.68万 - 项目类别: